Clayton Alexander, DO
Family Medicine · la Porte, INNPI 1992794879
Payments from drug & device makers
Across 201 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supreme Orthopedic Systems, LLC$1K
- Astellas Pharma US Inc$391
- AbbVie$372
- Novartis$334
- GSK$314
- Pfizer$225
- plus $2K from 27 others
What the payments were for
- Food & beverage$2,96664%
- Education$1,65036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supreme Orthopedic Systems, LLC | 1 | $1,200 |
| Astellas Pharma US Inc | 5 | $391 |
| AbbVie(2 entities) | 31 | $372 |
| Novartis | 25 | $334 |
| GSK | 24 | $314 |
| Pfizer | 11 | $225 |
| Merck | 12 | $218 |
| Lilly USA, LLC | 11 | $166 |
| Bayer | 8 | $147 |
| Biohaven Pharmaceuticals, Inc. | 4 | $118 |
| Jazz Pharmaceuticals Inc. | 6 | $116 |
| AstraZeneca | 7 | $106 |
| Boehringer Ingelheim | 6 | $100 |
| Sanofi-aventis U.S. LLC | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Mylan Specialty L.p. | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Abbott | 3 | $62 |
| Novo Nordisk | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Dermira, Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $16 |
| Insulet Corporation | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
How this compares
$4,616 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 123 | $145,278 |
| EliquisApixaban | 130 | $97,179 |
| OzempicSemaglutide | 81 | $92,006 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $51,571 |
| FarxigaDapagliflozin Propanediol | 38 | $45,310 |
| TrulicityDulaglutide | 34 | $40,201 |
| XareltoRivaroxaban | 41 | $38,138 |
| MounjaroTirzepatide | 32 | $32,023 |
| RybelsusSemaglutide | 19 | $31,023 |
| EntrestoSacubitril/Valsartan | 32 | $30,649 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $30,040 |
| SynjardyEmpagliflozin/Metformin Hcl | 25 | $21,788 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $21,361 |
| JanuviaSitagliptin Phosphate | 19 | $21,212 |
| LinzessLinaclotide | 25 | $18,818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Stiolto Respimat | $100 | $176,144161 claims |
| Novo NordiskOzempic, Rybelsus | $46 | $123,029100 claims |
| PfizerEliquis | $225 | $97,179130 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $166 | $72,22366 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $314 | $63,04878 claims |
| AstraZenecaFarxiga | $106 | $45,31038 claims |
| Johnson & JohnsonXarelto, Invokana | $14 | $44,60552 claims |
| NovartisEntresto | $334 | $30,64932 claims |
| AbbVieLinzess, Fetzima | $372 | $24,73537 claims |
| MerckJanuvia | $218 | $21,21219 claims |
| Astellas Pharma US IncMyrbetriq | $391 | $12,93813 claims |
| BayerKerendia | $147 | $7,22912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in la Porte
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.